SCHEMBL4447783

SCHEMBL4447783

COCOc1cc(O)c(C(=O)C=Cc2ccccc2)c(OCOC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
KMT2A Q03164 4/20 0.68
CYP3A4 P08684 3/20 0.68
ATM Q13315 2/20 0.68
TP53 P04637 2/20 0.68
HSD17B10 Q99714 1/20 0.68
MAOA P21397 2/20 0.63
MAOB P27338 2/20 0.63
CYP19A1 P11511 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
MEN1 O00255 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
KCNA3 P22001 1/20 0.62
ABCG2 Q9UNQ0 5/20 0.56
NFKB1 P19838 1/20 0.56
DPP4 P27487 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
SLC5A1 P13866 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447777 1.00 MAPT (0.68) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL30382156 1.00 MAPT (0.68) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL25210849 0.94 MAPT (0.78) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL16751995 0.93 MAPT (0.56) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL16751996 0.93 MAPT (0.56) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL9578210 0.92 ABCG2 (0.64) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL9578204 0.92 ABCG2 (0.64) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL25235778 0.90 SLC5A1 (0.69) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL25221421 0.90 MAPT (0.61) MAPTKMT2ACYP3A4ATMTP53
SCHEMBL25221425 0.90 MAPT (0.61) MAPTKMT2ACYP3A4ATMTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20090221568-A1 Synthesis of Inhibitors of FtsZ NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-09-03 US disclosed
EP-1957474-A1 SYNTHESIS OF INHIBITORS OF FTSZ PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-08-20 EP disclosed
WO-2007056188-A1 SYNTHESIS OF INHIBITORS OF FTSZ PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221568-A1 Synthesis of Inhibitors of FtsZ CDC42, CCNB1, CDC20 MAPT 1355/4885KMT2A 2739/4885CYP3A4 2755/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885CYP3A4 928/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885CYP3A4 1589/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885CYP3A4 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.